Induction of tolerogenic dendritic cells by IL-6-secreting CT26 colon carcinoma

Immunopharmacology and Immunotoxicology

Volumn 34, Issue 3, 2012, Pages 465-469

  Alshamsan, Aws ^a,b  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

Colon cancer; Dendritic cells; IL 6; Immunotherapy; STAT3

Indexed keywords

CD40 ANTIGEN; CD86 ANTIGEN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; STAT3 PROTEIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE MARROW; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CELL LINEAGE; CELL MATURATION; COLON CARCINOMA; DENDRITIC CELL; DOWN REGULATION; FLOW CYTOMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANIMALS; ANTIGENS, CD40; ANTIGENS, CD86; CELL LINE, TUMOR; COLONIC NEOPLASMS; DENDRITIC CELLS; IMMUNE TOLERANCE; IMMUNOTHERAPY; INTERLEUKIN-6; MICE; MICE, INBRED BALB C; NEOPLASM PROTEINS; NIH 3T3 CELLS; PHOSPHORYLATION; STAT3 TRANSCRIPTION FACTOR;

MURINAE;

EID: 84860775890     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.3109/08923973.2011.625034     Document Type: Article

References (23)

1. Hanahan, D., Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646-674.
2. Apetoh, L., Locher, C., Ghiringhelli, F., Kroemer, G., Zitvogel, L. Harnessing dendritic cells in cancer. Semin Immunol 2011, 23, 42-49.
3. Nefedova, Y., Gabrilovich, D.I. Targeting of Jak/STAT pathway in antigen presenting cells in cancer. Curr Cancer Drug Targets 2007, 7, 71-77. (Pubitemid 46345509)
4. Haura, E.B., Turkson, J., Jove, R. Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol 2005, 2, 315-324. (Pubitemid 40903176)
5. Yu, H., Jove, R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 2004, 4, 97-105. (Pubitemid 38198738)
6. Liu, X., Li, J., Zhang, J. STAT3-decoy ODN inhibits cytokine autocrine of murine tumor cells. Cell Mol Immunol 2007, 4, 309-313.
7. Chen, Z., Han, Z.C. STAT3: A critical transcription activator in angiogenesis. Med Res Rev 2008, 28, 185-200. (Pubitemid 351281185)
8. Kortylewski, M., Yu, H. Role of STAT3 in suppressing anti-tumor immunity. Curr Opin Immunol 2008, 20, 228-233.
9. Hoentjen, F., Sartor, R.B., Ozaki, M., Jobin, C. STAT3 regulates NF-?B recruitment to the IL-12p40 promoter in dendritic cells. Blood 2005, 105, 689-696. (Pubitemid 40070754)
10. Lutz, M.B., Kukutsch, N., Ogilvie, A.L., Rössner, S., Koch, F., Romani, N., Schuler, G. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999, 223, 77-92. (Pubitemid 29096240)
11. Bharadwaj, U., Li, M., Zhang, R., Chen, C., Yao, Q. Elevated interleukin-6 and G-CSF in human pancreatic cancer cell conditioned medium suppress dendritic cell differentiation and activation. Cancer Res 2007, 67, 5479-5488. (Pubitemid 46997289)
12. Alshamsan, A., Hamdy, S., Das, S., Lavasanifar, A., Samuel, J., El-Kadi, A.O. Validation of bone marrow derived dendritic cells as an appropriate model to study tumor-mediated suppression of DC maturation through STAT3 hyperactivation. J Pharm Pharm Sci 2010, 13, 21-26.
13. Kushwah, R., Hu, J. Role of dendritic cells in the induction of regulatory T cells. Cell Biosci 2011, 1, 20.
14. Kalinski, P., Hilkens, C.M., Wierenga, E.A., Kapsenberg, M.L. T-cell priming by type-1 and type-2 polarized dendritic cells: The concept of a third signal. Immunol Today 1999, 20, 561-567.
15. Trombetta, E.S., Mellman, I. Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol 2005, 23, 975-1028. (Pubitemid 40563191)
16. Yu, H., Kortylewski, M., Pardoll, D. Crosstalk between cancer and immune cells: Role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007, 7, 41-51. (Pubitemid 46020826)
17. Vicari, A.P., Caux, C., Trinchieri, G. Tumour escape from immune surveillance through dendritic cell inactivation. Semin Cancer Biol 2002, 12, 33-42. (Pubitemid 34087896)
18. Gabrilovich, D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 2004, 4, 941-952. (Pubitemid 39620069)
19. Zou, W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005, 5, 263-274. (Pubitemid 40488632)
20. Yanagawa, Y., Iwabuchi, K., Ono?, K. Co-operative action of interleukin-10 and interferon-γ to regulate dendritic cell functions. Immunology 2009, 127, 345-353.
21. Matsumura, Y., Kobayashi, T., Ichiyama, K., Yoshida, R., Hashimoto, M., Takimoto, T., Tanaka, K., Chinen, T., Shichita, T., Wyss-Coray, T., Sato, K., Yoshimura, A. Selective expansion of foxp3-positive regulatory T cells and immunosuppression by suppressors of cytokine signaling 3-deficient dendritic cells. J Immunol 2007, 179, 2170-2179.
22. DeMatos, P., Abdel-Wahab, Z., Vervaert, C., Hester, D., Seigler, H. Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice. J Surg Oncol 1998, 68, 79-91. (Pubitemid 28269975)
23. Furumoto, K., Soares, L., Engleman, E.G., Merad, M. Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. J Clin Invest 2004, 113, 774-783. (Pubitemid 38544171)